Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Bortezomib, Ifosfamide, and Vinorelbine in Treating Young Patients With Hodgkin`s Lymphoma That is Recurrent or Did Not Respond to Previous Therapy


A Phase II Study of Bortezomib (Velcade, PS-341, IND # 58443) in Combination With Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults With Refractory/Recurrent Hodgkin Disease


Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as ifosfamide and vinorelbine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may help ifosfamide and vinorelbine work better by making cancer cells more sensitive to the drugs. Giving bortezomib together with ifosfamide and vinorelbine may kill more cancer cells.


This phase II trial is studying the side effects and how well giving bortezomib together with ifosfamide and vinorelbine works in treating young patients with Hodgkin`s lymphoma that is recurrent or did not respond to previous therapy.

Study Status: Recruiting

Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente 866-223-8100

Condition Intervention Phase
Lymphoma Drug: bortezomib
Drug: filgrastim
Drug: ifosfamide
Drug: vinorelbine ditartrate
Procedure: chemosensitization/potentiation therapy
Procedure: chemotherapy
Procedure: colony-stimulating factor therapy
Procedure: enzyme inhibitor therapy
Phase 2

Verified by Children`s Oncology Group April, 2008

Sponsored by: Children`s Oncology Group
Information provided by: National Cancer Institute (NCI) identifier: NCT00381940

Study Type: Interventional

Study Design: Treatment, Open Label

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Terzah M. Horton, MD, PhD., Study Chair
Richard A. Drachtman, MD.,

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site